Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Alnylam Pharmaceuticals, Inc.
Company typePublic
Traded as
  • Nasdaq: ALNY
  • Russell 1000 component
IndustryPharmaceutical
Founded2002 (2002)
HeadquartersCambridge, Massachusetts, U.S.
Key people
Yvonne Greenstreet (CEO)
Revenue US$219.75 million (2019)
US$74.91 million (2018)
Number of employees
1,323 (2019)
Websitealnylam.com
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.